These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29701508)

  • 1. Heart rate variability testing: could it change spending for rheumatoid arthritis patients in the United States? An exploratory economic analysis.
    Zimmermann M; Vodicka E; Holman AJ; Garrison LP
    J Med Econ; 2018 Jul; 21(7):712-720. PubMed ID: 29701508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
    Bansback NJ; Regier DA; Ara R; Brennan A; Shojania K; Esdaile JM; Anis AH; Marra CA
    Drugs; 2005; 65(4):473-96. PubMed ID: 15733011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.
    Stevenson MD; Wailoo AJ; Tosh JC; Hernandez-Alava M; Gibson LA; Stevens JW; Archer RJ; Simpson EL; Hock ES; Young A; Scott DL
    J Rheumatol; 2017 Jul; 44(7):973-980. PubMed ID: 28202743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States.
    Bognar K; Shafrin J; Brauer M; Zhao L; Hockett R; O'Neil M; Jena A
    J Med Econ; 2018 Nov; 21(11):1057-1066. PubMed ID: 30019600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico.
    Tundia N; Kotze PG; Rojas Serrano J; Mendes de Abreu M; Skup M; Macaulay D; Signorovitch J; Chaves L; Chao J; Bao Y
    J Med Econ; 2016 Dec; 19(12):1187-1199. PubMed ID: 27376404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
    Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
    J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis.
    Tanno M; Nakamura I; Ito K; Tanaka H; Ohta H; Kobayashi M; Tachihara A; Nagashima M; Yoshino S; Nakajima A
    Mod Rheumatol; 2006; 16(2):77-84. PubMed ID: 16633926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of introducing biologics to patients with rheumatoid arthritis in Taiwan: a population-based trend study.
    Lang HC; Lee HC; Lee SS; Lin HY; Chiu YM
    Int J Rheum Dis; 2016 Nov; 19(11):1112-1118. PubMed ID: 26890537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study.
    Joensuu JT; Aaltonen KJ; Aronen P; Sokka T; Puolakka K; Tuompo R; Korpela M; Vasala M; Ilva K; Nordström D; Blom M
    Rheumatology (Oxford); 2016 Oct; 55(10):1803-11. PubMed ID: 27354689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct and indirect healthcare costs of rheumatoid arthritis patients in Turkey.
    Hamuryudan V; Direskeneli H; Ertenli I; Inanc M; Karaaslan Y; Oksel F; Ozbek S; Pay S; Terzioglu E; Balkan Tezer D; Hacibedel B; Akkoc N
    Clin Exp Rheumatol; 2016; 34(6):1033-1037. PubMed ID: 27749224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States.
    Claxton L; Taylor M; Gerber RA; Gruben D; Moynagh D; Singh A; Wallenstein GV
    Curr Med Res Opin; 2018 Nov; 34(11):1991-2000. PubMed ID: 29976110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
    Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
    Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The burden of rheumatoid arthritis and access to treatment: health burden and costs.
    Lundkvist J; Kastäng F; Kobelt G
    Eur J Health Econ; 2008 Jan; 8 Suppl 2():S49-60. PubMed ID: 18157732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.
    Yang M; Galebach PJ; Signorovitch JE; Garg V
    Clin Exp Rheumatol; 2017; 35(5):791-798. PubMed ID: 28339358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.